{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:38:33Z","timestamp":1788903513129,"version":"build-2803163510"},"reference-count":21,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2025]]},"DOI":"10.70352\/scrj.cr.24-0134","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:07:47Z","timestamp":1744150067000},"page":"n\/a","source":"Crossref","is-referenced-by-count":2,"title":["Successful Conversion Surgery Following S-1 Plus Oxaliplatin Combined with Nivolumab Therapy for a Preoperatively Diagnosed Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report"],"prefix":"10.70352","volume":"11","author":[{"given":"Mizuki","family":"Fukuda","sequence":"first","affiliation":[{"name":"Department of Surgery, The Jikei University, Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Jikei University, Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Jikei University, Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Toya","sequence":"additional","affiliation":[{"name":"Department of Surgery, The Jikei University, Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Sasuga","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Jikei University, Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Jikei University, Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syun","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Jikei University, Kashiwa Hospital, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"51119","reference":[{"key":"1","unstructured":"1) Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma. 15th Ed. Kanehara Publishing; 2017. (in Japanese)"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Matsunou H, Konishi F, Jalal RE, et al. Alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. Cancer 1994; 73: 534\u201340.","DOI":"10.1002\/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Matsumoto K, Ueyama H, Matsumoto K, et al. Clinicopathological features of alpha-fetoprotein producing early gastric cancer with enteroblastic differentiation. World J Gastroenterol 2016; 22: 8203\u201310.","DOI":"10.3748\/wjg.v22.i36.8203"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Murakami T, Yao T, Mitomi H, et al. Clinicopathologic and immunohistochemical characteristics of gastric adenocarcinoma with enteroblastic differentiation: a study of 29 cases. Gastric Cancer 2016; 19: 498\u2013507.","DOI":"10.1007\/s10120-015-0497-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Akazawa Y, Saito T, Hayashi T, et al. Next-generation sequencing analysis for gastric adenocarcinoma with enteroblastic differentiation: emphasis on the relationship with hepatoid adenocarcinoma. Hum Pathol 2018; 78: 79\u201388.","DOI":"10.1016\/j.humpath.2018.04.022"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fujimoto M, Matsuzaki I, Nishino M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. J Clin Pathol 2018; 71: 600\u20137.","DOI":"10.1136\/jclinpath-2017-204928"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kuroda N, Yorita K. Clinicopathologic study of 10 cases of gastric adenocarcinoma with hepatoid or enteroblastic differentiation. Pol J Pathol 2018; 69: 128\u201335.","DOI":"10.5114\/pjp.2018.76696"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Wang Y, Wei X, Ke B, et al. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation. Histopathology 2023; 83: 631\u201346.","DOI":"10.1111\/his.14998"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clear-cell, and \u03b1-fetoprotein-producing gastric carcinomas. Cancer Sci 2009; 100: 626\u201332.","DOI":"10.1111\/j.1349-7006.2009.01108.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol 2010; 34: 533\u201340.","DOI":"10.1097\/PAS.0b013e3181d1dcdd"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kinjo T, Taniguchi H, Kushima R, et al. Histologic and immunohistochemical analyses of \u03b1-fetoprotein- producing cancer of the stomach. Am J Surg Pathol 2012; 36: 56\u201365.","DOI":"10.1097\/PAS.0b013e31823aafec"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yamada R, Horiguchi S-I, Onishi T, et al. Early gastric cancer with purely enteroblastic differentiation and no conventional adenocarcinoma component. Case Rep Pathol 2018; 2018: 3620293.","DOI":"10.1155\/2018\/3620293"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kimura T, Hikichi T, Nakamura J, et al. Gastric adenocarcinoma with enteroblastic differentiation followed endoscopically: a case report. Clin J Gastroenterol 2020; 13: 1074\u201382.","DOI":"10.1007\/s12328-020-01220-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kang Y-K, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 2461\u201371.","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27\u201340.","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 2023; 26: 1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Jun C, Yamauchi S, Yube Y, et al. Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer. Surg Case Rep 2023; 9: 86.","DOI":"10.1186\/s40792-023-01668-x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ferreira JE, Mbagwu E, Lee EY, et al. Cytopathological features of gastroesophageal junction adenocarcinoma with enteroblastic differentiation and histopathological correlation. Cytopathology 2023; 34: 250\u20133.","DOI":"10.1111\/cyt.13198"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Matsuyama S, Fukuda A, Matsumoto A, et al. Two cases of gastric adenocarcinoma with enteroblastic differentiation which demonstrated rapid progressive courses. Intern Med 2024.","DOI":"10.2169\/internalmedicine.3913-24"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kano Y, Ichikawa H, Hanyu T, et al. Conversion surgery for stage IV gastric cancer: a multicenter retrospective study. BMC Surg 2022; 22: 428.","DOI":"10.1186\/s12893-022-01874-8"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Takeno A, Motoori M, Kishi K, et al. Prognostic factors of conversion surgery for stage IV gastric cancer: a multi-institutional retrospective analysis. Ann Gastroenterol Surg 2024; 8: 431\u201342.","DOI":"10.1002\/ags3.12778"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.24-0134\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:19:16Z","timestamp":1744431556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/11\/1\/11_cr.24-0134\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.24-0134","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"cr.24-0134"}}